Kenvue Inc

Kenvue Inc(KVUE)の株式分析

$18.910

+0.244 (+1.29%)終値時点

Loading chart…
高値
18.945
始値
18.740
出来高加重平均価格
18.86
出来高
27.69M
時価総額
35.27B
安値
18.715
売買代金
522.22M
EV/EBITDA(TTM)
11.79

Kenvue Inc. is a consumer health company. The Company's differentiated portfolio of brands includes Aveeno, BAND-AID Brand, Johnson's, Listerine, Neutrogena, Nicorette, Tylenol, and Zyrtec. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee's, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women's health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).

www.kenvue.com

AI分析 of Kenvue Inc (KVUE)

買い

Kenvue Inc is a good buy right now as it is currently priced at $18.91, which is below the analyst price targets of $19 from both UBS and Barclays. The stock has shown a strong upward trend with a 5-day change of +6.84% and a year-to-date change of +9.18%. However, the main risk is its high P/E ratio of 49.26, which indicates that it may be overvalued relative to its earnings.

アナリスト評価(1)

-0.26% 下落余地
売り
0 買い
0 中立
1 売り
現在: 18.91
安値
17.00
平均
18.86
高値
23.00

UBS

2026-08-11

目標株価

$19

中立

Barclays

2026-07-21

目標株価

$19

Equal Weight

UBS

2026-07-16

目標株価

$20

中立

Citi

2026-04-15

目標株価

$19

中立

Barclays

2026-04-14

目標株価

$18

Equal Weight

バリュエーション指標

Kenvue Inc(KVUE)の現在の予想PERは14.73で、5年平均は17.52です。

予想PER

割安
5年平均 P/E
17.52
現在のP/E
14.73
割高
19.72
割安
15.32

予想EV/EBITDA

適正
5年平均 EV/EBITDA
12.65
現在のEV/EBITDA
11.79
割高
13.79
割安
11.50

予想PSR

適正
5年平均 P/S
2.48
現在のP/S
2.25
割高
2.81
割安
2.15

Alphio AI による KVUE の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%KVUE

$25.34

シナリオ価格

基

基本

基本 · 50%KVUE

$22.26

シナリオ価格

弱

弱気

弱気 · 25%KVUE

$19.40

シナリオ価格

KVUE を保有するクジラ

I

Ingalls & Snyder, LLC

+ を保有KVUE

+9.84%

3か月リターン

Y

Yacktman Asset Management LP

+ を保有KVUE

+7.03%

3か月リターン

T

Trajan Wealth, L.L.C.

+ を保有KVUE

+5.22%

3か月リターン

S

Saturna Capital Corporation

+ を保有KVUE

+4.14%

3か月リターン

S

Starboard Value LP

+ を保有KVUE

+3.12%

3か月リターン

M

Magnetar Capital Partners, LP

+ を保有KVUE

+2.74%

3か月リターン

KVUE のよくある質問 — Alphio AI が回答

Kenvue Inc. is a consumer health company. The Company's differentiated portfolio of brands includes Aveeno, BAND-AID Brand, Johnson's, Listerine, Neutrogena, Nicorette, Tylenol, and Zyrtec. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee's, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women's health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM). It operates in the Consumer Non-Cyclicals sector (PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS industry).

Kenvue Inc is a good buy right now as it is currently priced at $18.91, which is below the analyst price targets of $19 from both UBS and Barclays. The stock has shown a strong upward trend with a 5-day change of +6.84% and a year-to-date change of +9.18%. However, the main risk is its high P/E ratio of 49.26, which indicates that it may be overvalued relative to its earnings.

1 analysts cover KVUE: 0 rate it Buy, 0 Hold and 1 Sell. The average price target is 18.86.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める